1104 adu briefing docs
Jolygon / iStock / Getty Images

Product Development

FDA signals relatively clear path ahead for Alzheimer’s therapy aducanumab

Friday’s advisory committee meeting on Biogen’s mAb may be a support-building exercise

Nov 5, 2020 | 3:26 AM GMT

FDA appears to be leaning toward approval of the first theoretically disease-modifying therapy for Alzheimer’s disease, or any neurodegenerative disorder, based on two incomplete Phase III trials, one of which met its primary endpoint with modeling of the missing data, and another that failed to show even a trend toward significance.

Materials released ahead of Friday’s advisory committee meeting to discuss the anti-amyloid therapy aducanumab reveal that FDA’s interpretation of the data aligns with the arguments from

Read the full 1142 word article

How to gain access

Continue reading with a
two-week free trial.